Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986142

Next Previous
Drug Profile

BMS 986142

Alternative Names: BMS-986142

Latest Information Update: 05 Mar 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 05 Mar 2021 No development reported - Phase-II for Rheumatoid arthritis (Treatment-experienced) in USA, Canada, Canada, Mexico, Spain, Austria, Japan, Russia, South Africa, Belgium, Taiwan, Argentina, Brazil, Chile, Colombia, Czech Republic, France, Germany, Israel, Italy, Netherlands, Poland, South Korea (PO)
  • 05 Mar 2021 No development reported - Phase-II for Sjogren's syndrome in USA, Puerto Rico, Australia, Chile, Colombia, Italy, Mexico, Peru, Poland, Russia, South Africa (PO)
  • 07 Jun 2018 Bristol-Myers Squibb completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Russia, South Africa, South Korea, Spain, Taiwan, USA (PO) (NCT02638948) (EudraCT2015-002887-17)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top